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Abstract
Background: Coronary artery disease (CAD) shares common risk factors with type 2 diabetes (T2DM). Variations in the
transcription factor 7-like 2 (TCF7L2) gene, particularly rs7903146, increase T2DM risk. Potential links between genetic
variants of the TCF7L2 locus and coronary atherosclerosis are uncertain. We therefore investigated the association between
TCF7L2 polymorphisms and angiographically determined CAD in diabetic and non-diabetic patients.
Methodology/Principal Findings: We genotyped TCF7L2 variants rs7903146, rs12255372, and rs11196205 in a cross-
sectional study including 1,650 consecutive patients undergoing coronary angiography for the evaluation of established or
suspected stable CAD. Significant CAD was diagnosed in the presence of coronary stenoses $50%. Variant rs7903146 in the
total study cohort was significantly associated with significant CAD (adjusted additive OR=1.29 [1.09–1.53]; p=0.003). This
association was strong and significant in T2DM patients (n=393; OR=1.91 [1.32–2.75]; p=0.001) but not in non-diabetic
subjects (OR=1.09 [0.90–1.33]; p=0.370). The interaction risk allele by T2DM was significant (pinteraction=0.002), indicating a
significantly stronger impact of the polymorphism on CAD in T2DM patients than in non-diabetic subjects. TCF7L2
polymorphisms rs12255372 and rs11196205 were also significantly associated with CAD in diabetic patients (adjusted
additive OR=1.90 [1.31–2.74]; p=0.001 and OR=1.75 [1.22–2.50]; p=0.002, respectively). Further, haplotype analysis
demonstrated that haplotypes including the rare alleles of all investigated variants were significantly associated with CAD in
the whole cohort as well as in diabetic subjects (OR=1.22 [1.04–1.43]; p=0.013 and OR=1.67 [1.19–2.22]; p=0.003,
respectively).
Conclusions/Significance: These results suggest that TCF7L2 variants rs7903146 rs12255372, and rs11196205 are
significantly associated with angiographically diagnosed CAD, specifically in patients with T2DM. TCF7L2 therefore appears
as a genetic link between diabetes and atherosclerosis.
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Introduction
Type 2 diabetes (T2DM) confers a two- to threefold increased
risk of coronary artery disease (CAD) [1,2]. Importantly, T2DM
and CAD share common risk factors and both diseases show a
strong genetic background [3–5]. Recently, transcription factor 7-
like 2 (TCF7L2), located on chromosome 10q25.3, has been
identified as a major T2DM susceptibility gene [6]. Single
nucleotide polymorphisms (SNPs) of TCF7L2 have been consis-
tently associated with T2DM in populations of different ethnic
descent, making TCF7L2 one of the most important locus known
today to predispose for T2DM [7–9]. Among noted SNPs, variant
rs7903146 was found to be most significantly associated with
T2DM risk [6–9]. Further, TCF7L2 SNPs rs12255372 and
rs11196205 have been linked with impaired glucose metabolism
[8–10] and an increased diabetes risk. [6,8,9].
Several studies have shown that TCF7L2 influences the risk of
T2DM via impairment of beta-cell function (BCF) [11,12].
However, the exact mechanisms through which TCF7L2 affects
the susceptibility to T2DM remain unclear [13,14]. The gene
TCF7L2 encodes the transcription factor TCF-4 [15], which serves
as a nuclear receptor for beta-catenin in the Wingless-type (Wnt)
signalling pathway [16]. The beta-catenin/TCF-4 transcriptional
complex is involved in a variety of biological events. In particular, it
has been shown to play an important role in vascular remodelling
through the regulation of smooth muscle cell proliferation and
endothelial cell growth [17–19]. TCF7L2 may therefore contribute
not only to the development of T2DM but also to the development
of CAD. However potential links between genetic variants of the
TCF7L2 locus and CAD are uncertain [20,21].
We therefore aimed at investigating the association of the
TCF7L2 SNPs rs7903146, rs12255372, and rs11196205 with
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consecutive patients undergoing coronary angiography. In partic-
ular, we investigated whether the association between TCF7L2
polymorphisms and angiographically characterized CAD differs
between patients with diabetes and non-diabetic individuals.
Results
Characteristics of the study population
Overall, the characteristics of our patients were typical for
patients undergoing coronary angiography for the evaluation of
CAD, with a preponderance of male gender (66.4%) and a high
prevalence of T2DM (23.8%), hypertension (53.5%), and smoking
(59.1%). Coronary angiography revealed significant coronary
stenoses in 57.6% of the patients; 58.3% of our patients with
diabetes were on anti-diabetic medication. Clinical and biochem-
ical characteristics according to the presence of T2DM are
summarized in table 1.
Genoytping analysis
Genotypes were successfully called in 1,650 patients for SNP
rs7903146 (100%), in 1,645 patients for SNP rs12255372 (99.7%),
and in 1,644 patients for SNP rs11196205 (99.6%). Results of
re-genotyping analysis of 92 randomly selected samples were
100% in agreement with the initial genotyping results and all
three TCF7L2 SNP genotype frequencies did not deviate
significantly from Hardy-Weinberg equilibrium (respective
Chi-squared values as well as p-values are given in table S1).
These genotyping quality controls all indicate a high genotyping
data quality. Further, the analysed TCF7L2 SNPs were in
linkage disequilibrium: Pairwise squared correlation coefficients
were r
2=0.747 between rs7903146 and rs12255372, r
2=0.491
between rs7903146 and rs11196205, and r
2=0.461 between
rs12255372 and rs11196205.
Association of TCF7L2 variants with clinical and
biochemical subject characteristics
Associations between TCF7L2 variants rs7903146, rs12255372,
and rs11196205 and subject characteristics in the total cohort, as
well as in patients with T2DM and in non-diabetic subjects are
presented in tables S2, S3, and S4, respectively. Variants
rs7903146 and rs12255372 were significantly associated with
increased glucose levels, as well with a reduced HOMA index of
beta cell function in the total cohort. Further, variants rs7903146
and rs12255372 were significantly associated with T2DM in our
study population (additive OR=1.33 [1.13–1.58]; p=0.001, and
OR=1.36 [1.15–1.61]; p,0.001, respectively). Also, for both
variants diabetes duration significantly increased from the
homozygous genotype of the common allele, over the heterozy-
gous genotype, to the homozygous genotype of the rare allele
(7.768.6, 8.167.3, and 9.266.8 years, p=0.024 for variant
rs7903146 and 7.568.4, 8.567.5, and 9.066.6 years, p=0.045
for variant rs12255372). Variant rs11196205 was neither associ-
ated with T2DM nor with diabetes duration (p=0.058 and
p=0.547, respectively).
Association of TCF7L2 variants with angiographically
characterized CAD
Table 2 presents the prevalence of significant CAD according to
the genotypes of variants rs7903146, rs12255372, and
rs11196205, as well as allelic ORs from unadjusted and
multivariable logistic regression analysis. Regression models were
built in a stepwise manner: Model 1 is unadjusted, model 2 adjusts
for age, gender, BMI, smoking, hypertension, serum levels of HDL
cholesterol, LDL cholesterol, as well as for statin use, and model 3
for the covariates included in model 2 and, additionally, for serum
insulin and plasma glucose as well as for anti-diabetic medication
and haemoglobin A1c (HbA1c) levels. In all regression models,
variant rs7903146 proved significantly associated with angio-
Table 1. Clinical and biochemical subject characteristics with
respect to type 2 diabetes mellitus.
No T2DM T2DM P value
Individuals (n) 1257 393 -
Age (years) 63.7610.8 65.469.9 0.001
Male sex (%) 66.2 67.2 0.718
BMI (kg/m
2) 27.164.1 29.164.8 ,0.001
Hypertension (%) 52.1 58.0 0.041
Smoking (%) 57.0 65.6 0.002
Total cholesterol (mg/dl) 208645 192647 ,0.001
LDL cholesterol (mg/dl) 132638 118638 ,0.001
HDL cholesterol (mg/dl) 55617 49614 ,0.001
Triglycerides (mg/dl) 142690 1716112 ,0.001
Use of statins (%) 43.4 54.7 ,0.001
Insulin (mU/ml) 10.369.0 18.7645.6 ,0.001
Glucose (mmol/l) 5.460.7 8.462.7 ,0.001
HOMA IR 2.662.8 6.366.9 ,0.001
HOMA BCF 116689 86687 ,0.001
Differences in categorical variables were tested for statistical significance with
the Chi-square test. For continuous variables t-tests were applied. Non-normally
distributed variables [i.e. age, BMI, HDL cholesterol, LDL cholesterol,
triglycerides, fasting insulin, fasting glucose, homeostasis model assessment
(HOMA) insulin resistance (IR), and HOMA beta cell function (BCF)] were log-
transformed prior to statistical analysis. Continuous variables are given as mean
6 SD (of non log-transformed values).
doi:10.1371/journal.pone.0017978.t001
Table 2. Association between TCF7L2 variants and significant
coronary artery disease in the total cohort.
Variant rs7903146 rs12255372 rs11196205
Genotype CC CT TT GG GT TT GG GC CC
Frequency
CAD2 (%)
50.9 39.6 9.6 53.4 38.0 8.6 29.4 50.1 20.6
Frequency
CAD+ (%)
45.3 43.9 10.8 48.5 41.9 9.6 28.3 49.3 22.3
OR [95%CI]* 1.17 [1.01–1.36] 1.15 [0.99–1.34] 1.06 [0.92–1.21]
p* 0.038 0.073 0.432
OR [95%CI]{ 1.29 [1.09–1.53] 1.27 [1.07–1.51] 1.10 [0.94–1.29]
p{ 0.003 0.006 0.223
OR [95%CI] { 1.28 [1.07–1.54] 1.26 [1.04–1.51] 1.08 [0.91–1.29]
p{ 0.008 0.017 0.359
Additive odds ratios (OR), 95% confidence intervals (CI), and p-values were
calculated by logistic regression analyses: * Unadjusted. { Adjusted for age,
gender, BMI, smoking, hypertension, serum levels of HDL cholesterol, LDL
cholesterol, as well as for statin use. { Adjusted for the same covariates as in
model ({) and additionally for serum insulin, plasma glucose, haemoglobin A1c,
and anti-diabetic medication. CAD indicates coronary artery disease. T2DM
indicates type 2 diabetes mellitus.
doi:10.1371/journal.pone.0017978.t002
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association between variant rs12255372 and CAD was not
significant in unadjusted regression analysis, but became signifi-
cant in regression models 2 and 3. SNP rs11196205 was not
associated with CAD in any regression model.
Subgroup analysis with respect to the presence of T2DM
showed that all variants were significantly associated with CAD in
patients with T2DM, while they did not significantly influence
CAD risk in non-diabetic individuals. After further adjustment for
the duration of T2DM, the association between variant
rs7903146, rs12255372, and rs11196205 and CAD remained
significant among patients with diabetes (OR=2.34 [1.32–4.15];
p=0.004, OR=2.00 [1.34–3.00]; p=0.001, and OR=1.96
[1.32–2.91]; p=0.001, respectively).
To test whether the difference in the atherogenicity of variant
rs7903146 differed between patients with T2DM and non-diabetic
subjects in a statistically significant manner, interaction terms were
entered into logistic regression analyses (table 3). The interaction
terms ‘T2DM by SNP’ (additive model) of all investigated
TCF7L2 variants were significant indicating that TCF7L2
variants had a significantly stronger impact on CAD in patients
with T2DM than in non-diabetic patients. T2DM thus signifi-
cantly modulates the association of these TCF7L2 SNPs with
angiographically characterized CAD.
To further investigate the effect of elevated glucose levels on the
association between these variants and the presence of significant
coronary lesions we performed a subgroup analysis with respect
to subjects with impaired fasting glucose (n=448). Variants
rs7903146, rs12255372, and rs11196205 were not significantly
associated with CAD in this subgroup (OR=0.85 [0.63–1.13];
p=0.258, OR=0.75 [0.56–1.01]; p=0.057, and OR=0.86
[0.66–1.12], 0.258, respectively).
Table 3. Association between TCF7L2 variants and significant coronary artery disease with respect to the presence of type 2
diabetes mellitus.
Variant rs7903146 rs12255372 rs11196205
Presence of T2DM T2DM (2) T2DM (+) T2DM (2) T2DM (+) T2DM (2) T2DM (+)
Genotype CC CT TT CC CT TT GG GT TT GG GT TT GG GC CC GG GC CC
Frequency CAD2 (%) 51.5 38.4 10.1 48.1 44.4 7.5 53.6 37.5 8.8 52.3 40.2 7.6 29.0 49.7 21.3 31.1 51.5 17.4
Frequency CAD+ (%) 48.1 43.3 8.6 37.7 45.4 16.9 51.7 41.0 7.3 40.0 44.3 15.8 31.1 48.0 20.9 21.2 52.7 26.2
OR [95%CI]* 1.05 [0.88–1.24] 1.54 [1.12–2.12] 1.01 [0.85–1.20] 1.57 [1.14–2.16] 0.95 [0.81–1.11] 1.49 [1.09–2.03]
p* 0.611 0.007 0.934 0.006 0.532 0.012
pinteraction T2DMxSNP* 0.034 0.017 0.012
OR [95%CI]{ 1.09 [0.90–1.33] 1.91 [1.32–2.75] 1.06 [0.87–1.30] 1.90 [1.31–2.74] 0.95 [0.79–1.13] 1.75 [1.22–2.50]
p{ 0.370 0.001 0.540 0.001 0.557 0.002
pinteraction T2DMxSNP{ 0.002 0.001 0.001
OR [95%CI] { 1.09 [0.89–1.35] 2.02 [1.34–3.03] 1.06 [0.85–1.31] 2.01 [1.35–3.02] 0.91 [0.75–1.10] 1.98 [1.33–2.95]
p{ 0.410 0.001 0.604 0.001 0.322 0.001
pinteraction T2DMxSNP{ 0.003 0.002 ,0.001
Additive odds ratios (OR), 95% confidence intervals (CI), and p-values, as well as pinteraction-values were calculated by logistic regression analyses: * Unadjusted. {
Adjusted for age, gender, BMI, smoking, hypertension, serum levels of HDL cholesterol, LDL cholesterol, as well as for statin use. { Adjusted for the same covariates as in
model ({) and additionally for serum insulin, plasma glucose, haemoglobin A1c, and anti-diabetic medication. CAD indicates coronary artery disease. T2DM indicates
type 2 diabetes mellitus. SNP indicates single nucleotide polymorphism.
doi:10.1371/journal.pone.0017978.t003
Table 4. Association between TCF7L2 variants and the extent of coronary artery disease.
Variant Genotype All patients Non-diabetic patients Diabetic patients
Extent (±SD) p-value Extent (±SD) p-value Extent (±SD) p-value
rs7903146 CC 1.32 6 1.58 1.27 6 1.54 1.50 6 1.71
CT 1.46 6 1.66 0.053 1.38 6 1.63 0.963 1.70 6 1.70 0.043
TT 1.26 6 1.45 0.96 6 1.17 1.93 6 1.75
rs12255372 GG 1.34 6 1.58 1.30 6 1.57 1.49 6 1.65
GT 1.44 6 1.65 0.321 1.33 6 1.60 0.673 1.77 6 1.77 0.047
TT 1.28 6 1.46 1.00 6 1.24 1.84 6 1.69
rs11196205 GG 1.38 6 1.60 1.36 6 1.57 1.46 6 1.72
GC 1.38 6 1.62 0.983 1.30 6 1.63 0.209 1.63 6 1.60 0.058
CC 1.35 6 1.55 1.56 6 1.35 1.91 6 1.92
The extent of coronary artery disease was calculated as the number of significant coronary stenoses in a given patient. SD indicates standard deviation. P-values were
calculated by the Jonckheere-Terpstra-test.
doi:10.1371/journal.pone.0017978.t004
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angiographically characterized coronary atherosclerosis in our
patients, we investigated the association of these genetic variants
with the extent of coronary lesions, defined as the mean number of
significant coronary stenoses in a given patient (table 4). Variant
rs7903146 and rs12255372 were significantly associated with the
extent of CAD in patients with T2DM, while they did not
significantly influence the extent of CAD in non-diabetic
individuals or in the total study cohort. SNP rs11196205 was
associated with the extent of CAD in neither study subgroup.
Association of TCF7L2 haplotypes with angiographically
characterized CAD
Estimated frequencies of the five most common haplotypes and
their associations with CAD with respect to the presence of T2DM
are shown in table 5. The two frequent haplotype blocks including
either the common or the rare alleles of variants rs7903146,
rs12255372, and rs11196205 were significantly associated with
angiographically determined CAD in patients with T2DM. A
third common haplotype block carrying the common alleles of
variants rs7903146 and rs12255372, but the rare allele of variant
rs11196205 was not associated with the presence of CAD. Also,
remaining (less common) haplotypes were not associated with
significant coronary lesions. Neither haplotype in non-diabetic
subjects was associated with CAD. In the whole cohort, the
haplotype block including the rare alleles of TCF7L2 variants
showed significant association with CAD (table S5).
Discussion
In the present work, we report a positive association of the
TCF7L2 variants rs7903146, rs12255372, and rs11196205 with
coronary atherosclerosis, particularly in patients with T2DM.
Further, the results from our investigation are well in line with
numerous other studies consistently showing that TCF7L2 variants
rs7903146 and rs12255372 are associated with T2DM [6–9] and
influence the risk of diabetes via pancreatic beta cell dysfunction
[11,12]. Variant rs11196205 was not significantly associated with
T2DM. Also other studies found a weaker association between
diabetes and this variant compared to variant rs7903146 and
rs12255372, respectively [6,9]. However, variant rs11196205 was
significantly associated with CAD in diabetic patients in our study.
Further, haplotype analysis demonstrated that haplotypes including
the rare alleles of all investigated variants were significantly
associated with CAD in the whole cohort as well as in diabetic
subjects surpassing the effect of the individual SNPs. This
observation points to a combined effect of investigated SNPs on
the cardiovascular risk but also indicates that other SNPs located in
this haplotype may contribute to the development of CAD.
Of note, recently the Atherosclerosis Risk in Communities
(ARIC) Study did not find significant associations between
TCF7L2 SNPs and incident vascular events [20].
However, in contrast to vascular events, which constitute the
last step of atherothrombotic CAD and eventually are precipitated
by thrombogenic factors, coronary angiography preferentially
assesses atherosclerosis. Our data therefore indicate a role of
TCF7L2 in atherogenesis.
The TCF7L2 encoded protein TCF-4 plays a distinct role in the
Wnt signalling pathway [16], which has been shown to take part in
vascular remodelling by the regulation of smooth muscle cell
proliferation [17,19] and of endothelial cell growth [18].
Moreover, a crosstalk between the Wnt signalling pathway and
the nuclear factor-kappaB pathway has been proposed [22,23],
which regulates the expression of several inflammatory genes
implicated in atherosclerosis [24]. Of note, TCF7L2 variants are
associated with elevated blood glucose. Elevated glucose concen-
trations per se have been shown to activate nuclear factor k-B.
[25,26]. It therefore can be hypothesized that TCF7L2 may
influence the development of atherosclerosis i) by direct regulation
of smooth muscle cell proliferation and ii) by turning on nuclear
factor-kappaB pathway either directly through the Wnt signalling
pathway, or indirectly through increased blood glucose levels (via
impairment of beta cell function), or both, directly and indirectly.
Variants rs7903146, rs12255372, and rs11196205 in our study
were associated with significant CAD in particular in diabetic
individuals. It therefore can be further speculated that hypergly-
caemia, which in turn predisposes to a proinflammatory and
proatherogenic state is essential for the adverse impact of TCF7L2
on atherogenesis. However, even after adjustment for glucose and
HbA1c levels associations between TCF7L2 variants and CAD
remained significant in diabetic subjects. Therefore, relative
hyperglycaemia among patients with known T2DM does not
appear to explain the observed association. Another explanation
could be that, because subjects carrying TCF7L2 diabetic risk-
alleles are more likely to have progression from impaired glucose
tolerancetoT2DM[8],thedurationofexposureofT2DMcouldbe
longer in risk-allele carriers compared to diabetic patients with the
wild-type genotype, promoting the progress of atherogenesis.
Indeed, in our study polymorphisms rs7903146 and rs12255372
were significantly associated with diabetes duration. This relation
Table 5. Estimated frequency of common haplotypes and their associations with significant coronary artery disease with respect
to the presence of T2DM.
Non-diabetic patients Diabetic patients
Haplotype CAD (2) % CAD (+) % OR [95%CI] P value CAD (2) % CAD (+) % OR [95%CI] P value
rs7903146
C.T
rs12255372
G.T
rs11196205
G.C
C G G 53.1 54.6 1.06 [0.91–1.24] 0.468 55.6 45.8 0.67 [0.50–0.90] 0.009
C G C 15.6 13.7 0.86 [0.69–1.08] 0.193 11.8 12.0 1.03 [0.65–1.62] 0.908
C T C 1.9 1.0 0.53 [0.26–1.01] 0.050 2.8 2.4 0.86 [0.34–2.21] 0.755
T G C 3.5 3.5 1.01 [0.65–1.54] 0.983 4.6 3.0 0.66 [0.31–1.42] 0.286
T T C 25.2 26.7 1.08 [0.90–1.29] 0.410 24.3 35.1 1.67 [1.19–2.22] 0.003
ORs (odds ratios), 95%CIs (confidence intervals), and p values were calculated by chi-squared tests by comparing each haplotype to all remaining haplotypes. CAD
indicates coronary artery disease.
doi:10.1371/journal.pone.0017978.t005
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allele carriers but does not fully explain it: The variants in our
investigation remained associated with CAD after adjustment for
diabetes duration.
T2DM and CAD share common risk factors, but genes
associated with both conditions are rare [27,28]. We found that
TCF7L2 variants are associated with both T2DM and angio-
graphically diagnosed CAD, and that there are significant
interactions between diabetes status and atherogenicity. These
observations may point to a genetic link between diabetogenicity
and atherogenicity mediated by the TCF7L2 gene.
In contrast to our findings, a recent study by Sousa et al. [21]
found that the T-allele of TCF7L2 variant rs7903146 was
associated with a higher prevalence and severity of coronary
atherosclerosis in non-diabetic patients, but not in patients with
T2DM. From our data we cannot provide a definite explanation
for this discrepancy. It should be noted that there are some
differences between the two studies concerning subject character-
istics (e.g. mean age, prevalence of male sex and hypertension, as
well as plasma levels of cholesterol) and data analysis (e.g. additive
vs. dominant genetic model of inheritance), respectively, which
may contribute to the divergent findings. In addition, the patients
for the study by Sousa et al were recruited in Brazil and our
patients in Austria, Europe, which of course implies ethnical
differences. Whatsoever, our study provides approximately twice
the sample-size of the study by Sousa et al. [21] (1,650 vs. 896
patients) and firmly establishes our results at least for a white
European population.
Our study has strengths and limitations. An important strength
and central feature of our study design is the angiographical
characterisation of all subjects. By design, our study population of
angiographied coronary patients is selected; our results therefore
are not necessarily applicable to the general population. However,
the high-risk patient population we chose to investigate is of
particular clinical interest.
We conclude that TCF7L2 variants rs7903146, rs12255372,
and rs11196205 are significantly associated with angiographically
diagnosed CAD and that this association is significantly modulated
by the presence of T2DM. TCF7L2, therefore, appears as an
interesting candidate for a genetic link between atherogenesis and
diabetogenesis.
Materials and Methods
Ethics Statement
The study has been carried out in accordance with the
principles of the Declaration of Helsinki and the Ethics Committee
of the Medical University of Innsbruck approved the present
study; all participants gave written informed consent.
Study subjects
We investigated a total of 1,661 white patients undergoing
coronary angiography for the evaluation of suspected or established
stable CAD at the Department of Medicine and Cardiology of the
Academic Teaching Hospital Feldkirch, Austria. Ethnicity was
ascertained by clinical adjudgement and family history. Patients
with type 1 diabetes (n=11) were excluded, thus data are reported
for 1,650 individuals for the present study. Information on
conventional cardiovascular risk factors such as a history of
smoking, hypertension, or diabetes was obtained by a standardized
interview. BMI was calculated as body weight (kg)/height (m)
2.
T2DM was diagnosed according to WHO criteria [29], and
hypertension according to the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure [30] was defined as arterial blood pressure
greater than or equal to either 140 mm Hg systolic or 90 mm Hg
diastolic. Diagnosis of impaired fasting glucose was made on the
basis of fasting plasma glucose levels between 5.6 and 6.9 mmol/l
[31]. Statin use was defined as drug intake of at least one month.
Coronary angiography was performed with the Judkins technique
[32]. Significant CAD was diagnosed in the presence of significant
coronary stenoses with lumen narrowing of at least 50% and the
extent of CAD was calculated as the number of significant coronary
stenoses in a given patient, as described previously [33,34].
Measurement of biochemical variables
Venous blood samples were collected after an overnight fast of
12 hours before angiography was performed. The serum levels of
triglycerides, total cholesterol, LDL cholesterol, and HDL choles-
terol were determined by using enzymatic hydrolysis and
precipitation techniques (Triglycerides GPO-PAP, CHOD/PAP,
QuantolipLDL, QuantolipHDL; Roche, Basel, Switzerland) on a
Hitachi-Analyzer 717 or 911. Fasting glucose levels were measured
enzymatically from venous fluoride plasma by the hexokinase
method (Roche) on a Hitachi 717 or 911. Fasting serum insulin was
measured by an enzyme immunoassay on an AIA 1200 (Tosoh).
HbA1c was determined by high-performance liquid chromatogra-
phy on a Menarini-ArkrayKDKHA8140 (Arkray, Kyoto, Japan).
We estimated BCF and insulin resistance (IR) from fasting plasma
glucose and serum insulin using homeostasis model assessment
(HOMA) [35]. HOMA BCF was calculated by using the formula:
206 fasting insulin (mU/ml)/[fasting glucose (mmol/l) 23.5].
HOMA IR was calculated by using the formula: [fasting insulin
(mU/ml) 6fasting glucose (mmol/l)]/22.5.
Genotyping
Genomic DNA was extracted from EDTA blood or clotted
blood samples using the peqGOLDH Blood DNA Mini kit
(PEQLAB Biotechnologie Ltd., Erlangen, Germany). Genotyping
of TCF7L2 variants rs7903146, rs12255372, and rs11196205
were carried out by the 59 nuclease assay using TaqManH MGB
probes on a LightCyclerH 480 Real-Time PCR System (F.
Hoffmann-La Roche Ltd, Basel, Switzerland). TaqManH MGB
probes were provided together with corresponding PCR primers
by the Assay-on-demand
TM service (Applied Biosystems, Forster
City, CA). The 59 nuclease assay was performed in a 6 ml volume,
comprising 10–30 ng genomic DNA, 16 TaqManH Universal
PCR Master Mix (Applied Biosystems), and 16primer/probe mix
under the following amplification conditions: 10 min at 95uC and
40 cycles at 92uC for 15 s and 60uC for 1 min. Reference controls
as well as non template controls were included in each run.
Genotypes were automatically determined by LightCyclerHsoft-
ware 1.5 followed by a visual control of accurate genotype
classification. Further, genotyping of 92 randomly selected samples
was replicated to assess quality of SNP genotyping.
Statistical analysis
Differences in categorical variables were tested for statistical
significance with the Chi-square test. For continuous variables the
t-test and ANOVA were applied. The Kolmogorov-Smirnov test
was used to test, if continuous variables are normally distributed.
In addition, a normal quantile-quantile plot of residuals of each
variable was generated and visually inspected to test for normality.
Non-normally distributed variables (i.e. age, BMI, LDL choles-
terol, HDL cholesterol, triglycerides, fasting insulin, fasting
glucose, HbA1c, HOMA IR, and HOMA BCF, as well as
T2DM duration) were log-transformed prior to statistical analysis.
Further, logistic regression analyses were performed for evaluating
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PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e17978the association of the TCF7L2 variant with angiographically
characterized CAD. To evaluate the association of the TCF7L2
SNP with the extent of coronary lesions the Jonckheere-Terpstra-
test was applied. These statistical analyses were performed with the
software package SPSS 11.0 for Windows (SPSS, Inc., Chicago,
IL). Observed numbers of each genotype were compared with
those expected to test whether the sample was in Hardy-Weinberg
equilibrium using the Chi-Square test with one degree of freedom.
To measure linkage disequilibrium, the squared correlation
coefficient r
2 was calculated for each pair of SNPs using CubeX
software (http://www.oege.org/software/cubex [36]). Haplotype
frequencies were evaluated by the Estimate Haplotype (EH)
program (ftp://linkage.rockefeller.edu/software/eh [37]). The
distribution of continuous variables is given as mean 6 SD. (of
non log-transformed values). Statistical significance was defined as
a two-tailed p value ,0.05.
For power calculations the software package Quanto 1.2.3 was
used [38]. Power analysis was calculated for an additive model of
inheritance. On the basis of a minor allele frequency of 30% on
average of variants rs7903146 and rs12255372, and 46% of variant
rs11196205, respectively, reported in the literature for a European
population [7,8,10] and assuming a prevalence of significant
coronary stenoses of 60%, a priori power analysis indicated that
1,500 patients would be sufficient to demonstrate an OR of 1.25 for
rs7903146 and rs12255372 and an OR of 1.23 for rs11196205, at
an alpha fault of 0.05 with a power of 80%. Under the same
parameter settings 380 patients would be needed to demonstrate an
OR of 1.55 for rs7903146 and rs12255372 and an OR of 1.50 for
rs11196205, at an alpha fault of 0.05 with a power of 80%.
Supporting Information
Table S1 Testing for Hardy-Weinberg equilibrium. X
2
refers to chi-squared.
(DOC)
Table S2 Subject characteristics with respect to geno-
types of rs7903146. Differences in categorical variables were
tested for statistical significance with the Chi-square test. For
continuous variables ANOVA was applied. Non- normally
distributed variables [i.e. age, BMI, HDL cholesterol, LDL
cholesterol, triglycerides, fasting insulin, fasting glucose, homeo-
stasis model assessment (HOMA) insulin resistance (IR), HOMA
beta cell function (BCF), and haemoglobin A1c (HbA1c)] were log-
transformed prior to statistical analysis. Continuous variables are
given as mean 6 SD (of non log-transformed values).
(DOC)
Table S3 Subject characteristics with respect to geno-
types of rs12255372. Differences in categorical variables were
tested for statistical significance with the Chi-square test. For
continuous variables ANOVA was applied. Non- normally
distributed variables [i.e. age, BMI, HDL cholesterol, LDL
cholesterol, triglycerides, fasting insulin, fasting glucose, homeo-
stasis model assessment (HOMA) insulin resistance (IR), HOMA
beta cell function (BCF), and haemoglobin A1c (HbA1c)] were log-
transformed prior to statistical analysis. Continuous variables are
given as mean 6 SD (of non log-transformed values).
(DOC)
Table S4 Subject characteristics with respect to geno-
types of rs11196205. Differences in categorical variables study
were tested for statistical significance with the Chi-square test. For
continuous variables ANOVA was applied. Non- normally
distributed variables [i.e. age, BMI, HDL cholesterol, LDL
cholesterol, triglycerides, fasting insulin, fasting glucose, homeo-
stasis model assessment (HOMA) insulin resistance (IR), HOMA
beta cell function (BCF), and haemoglobin A1c (HbA1c)] were log-
transformed prior to statistical analysis. Continuous variables are
given as mean 6 SD (of non log-transformed values).
(DOC)
Table S5 Estimated frequency of common haplotypes
and their associations with significant coronary artery
disease. Odds ratios (OR), 95% confidence intervals (CI), and p-
values were calculated by chi-squared tests by comparing each
haplotype to all remaining haplotypes.
(DOC)
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